A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

Start: 2023-01-31Est. Completion: 2028-07-31

Enrollment target: 70 participants

Locations

City of Hope Nat'l Medical Center, Duarte, California, United States
Univ. of California - Irvine, Irvine, California, United States
UCLA Medical Center, Los Angeles, California, United States
Sarah Cannon Research Institute, Denver, Colorado, United States
Memorial Cancer Institute, Pembroke Pines, Florida, United States
University of Chicago, Chicago, Illinois, United States
Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
University of Maryland, Baltimore, Maryland, United States
Johns Hopkins University, Baltimore, Maryland, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Weill Cornell Medical College, New York, New York, United States
Motefiore-Einstein Center for Cancer Care, The Bronx, New York, United States
Novant Health, Winston-Salem, North Carolina, United States
Ohio State University, Columbus, Ohio, United States
Oregon Health and Science University, Portland, Oregon, United States
University of Pennsylvania-Abramson CCC-Dept. of Hem Onc, Philadelphia, Pennsylvania, United States
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
The University of Texas MD, Houston, Texas, United States

Trial Details